keyword
MENU ▼
Read by QxMD icon Read
search

Actinic keratosis

keyword
https://www.readbyqxmd.com/read/28427916/-actinic-keratosis-new-concept-and-therapeutic-update
#1
Rafael Carmena-Ramón, Almudena Mateu-Puchades, Sergio Santos-Alarcón, Sofía Lucas-Truyols
Actinic keratosis (AK) is a common reason for consultation in both Primary Care and Specialised Care. It is the third or fourth most common reason for consultation in dermatology, accounting for up to 5-6% of patients attended. It has also been observed that its prevalence has been increasing in the last 10years, compared to other dermatoses. This is also expected to continue to increase due to longer life expectancy, and by the changes in sun exposure habits since the middle of the last century. The aim of this article is to update the concepts of AK, cancerisation field and to present the currently available therapeutic tools...
April 17, 2017: Atencion Primaria
https://www.readbyqxmd.com/read/28421455/erratum-to-efficacy-and-safety-of-5-fluorouracil-0-5-salicylic-acid-10-in-the-field-directed-treatment-of-actinic-keratosis-a-phase-iii-randomized-double-blind-vehicle-controlled-trial
#2
Eggert Stockfleth, Ralph von Kiedrowski, Rolf Dominicus, John Ryan, Adam Ellery, Meritxell Falqués, Nathalie Ivanoff, Rosario Rodriguez Azeredo
No abstract text is available yet for this article.
April 18, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/28409583/long-term-follow-up-assessment-of-daylight-photodynamic-therapy-with-methyl-aminolevulinate-in-patients-with-actinic-keratosis
#3
Dario Fai, Carlotta Fai, Nicoletta Cassano, Gino A Vena
No abstract text is available yet for this article.
June 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28408848/ingenol-mebutate-in-low-amounts-for-the-treatment-of-actinic-keratosis-in-korean-patients
#4
Hyun Jae Joe, Byung Ho Oh
BACKGROUND: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK), has a drawback of inducing local skin reactions (LSRs), which may cause discomfort in patients. To reduce the LSRs, we tried the application of IM in low amounts. OBJECTIVE: The purpose of this study was to review Korean patients with AK being treated with IM and evaluate the LSRs and therapeutic outcomes of low amounts of IM. METHODS: We retrospectively reviewed 47 patients with AK on the face...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28406719/structured-expert-consensus-on-actinic-keratosis-treatment-algorithm-focusing-on-daylight-pdt
#5
Piergiacomo Calzavara-Pinton, Merete Hædersdal, Kirk Barber, Nicole Basset-Seguin, María Emilia Del Pino Flores, Peter Foley, Gaston Galimberti, Rianne Gerritsen, Yolanda Gilarbete, Sally Ibbotson, Ketty Peris, Sheetal Sapra, Eleni Sotiriou, Luis Torezan, Claas Ulrich, Jonathan Guillemot, Janek Hendrich, Rolf-Markus Szeimies
BACKGROUND: A practical and up-to-date consensus among experts is paramount to further improve patient care in actinic keratosis (AK). OBJECTIVES: To develop a structured consensus statement on the diagnosis, classification, and practical management of AK based on up-to-date information. METHODS: A systematic review of AK clinical guidelines was conducted. This informed the preparation of a 3-round Delphi procedure followed by a consensus meeting, which combined the opinions of 16 clinical experts from 13 countries, to construct a structured consensus statement and a treatment algorithm positioning daylight photodynamic therapy (dl-PDT) among other AK treatment options...
April 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28401585/a-proposed-scoring-system-for-assessing-the-severity-of-actinic-keratosis-on-the-head-actinic-keratosis-area-and-severity-index-akasi
#6
T Dirschka, G Pellacani, G Micali, J Malvehy, A J Stratigos, A Casari, L Schmitz, G Gupta
BACKGROUND: Actinic keratosis (AK) severity is currently evaluated by subjective assessment of patients. OBJECTIVE: To develop and perform an initial pilot validation of a new easy-to-use quantitative tool for assessing AK severity on the head. METHODS: The actinic keratosis area and severity index (AKASI) for the head was developed based on a review of other severity scoring systems in dermatology, in particular the psoriasis area and severity index (PASI)...
April 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28398427/disseminated-superficial-actinic-porokeratosis-treated-with-ingenol-mebutate-gel-0-05
#7
Isabella Anderson, Ethan T Routt, Shelbi C Jim On
Disseminated superficial actinic porokeratosis (DSAP) is a chronic condition characterized by numerous atrophic papules and patches with a distinctive peripheral keratotic ridge, typically found on sun-exposed areas. Treatment of DSAP is warranted not only for cosmetic and symptomatic benefits but also to prevent malignant transformation. Successful treatment of DSAP often is difficult and frequently requires the use of multiple modalities. Ingenol mebutate gel 0.05% is a topical medication primarily used for the treatment of actinic keratosis (AK) by inducing cell death...
March 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28394858/randomized-controlled-trial-of-fractional-carbon-dioxide-laser-resurfacing-followed-by-ultrashort-incubation-aminolevulinic-acid-blue-light-photodynamic-therapy-for-actinic-keratosis
#8
Macrene Alexiades
BACKGROUND: Aminolevulinic acid (ALA) photodynamic therapy (PDT) is an established treatment option for actinic keratosis (AK), and recently fractional carbon dioxide (CO2) laser was shown to improve outcomes; but studies of short incubation photosensitizer are lacking. OBJECTIVE: Assess the efficacy of short incubation ALA followed by blue light PDT with and without previous fractional CO2 treatment for the treatment of AK. METHODS: Randomized, paired split-design, controlled trial of fractional CO2 followed by ultrashort 15-minute versus 30-minute incubation ALA and blue light PDT for the treatment of AK on the face...
April 6, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28386508/suspected-pulmonary-metastasis-of-actinic-cutaneous-squamous-cell-carcinoma
#9
Monet E Meter, David J Nye, Christian R Galvez
Introduction. It is rare for actinic or squamous cell carcinoma (SCC) in situ to metastasize. Case Presentation. A 67-year-old male had a significant medical history including severe psoriatic arthritis treated with UVB, methotrexate, and rapamycin. He had twenty-five different skin excisions of actinic keratosis four of which were invasive SCC. Our patient developed shortness of breath necessitating a visit to the emergency department. A CT scan of his chest revealed a mass in the right lower lung. A subsequent biopsy of the mass revealed well-differentiated SCC...
2017: Case Reports in Surgery
https://www.readbyqxmd.com/read/28373119/photodynamic-therapy-effective-for-the-treatment-of-actinic-keratosis-and-basal-cell-carcinoma-in-bullous-pemphigoid-patients
#10
Theresa N Canavan, Salma Faghri de la Feld, Conway Huang, Naveed Sami
Treating skin cancers and extensive actinic keratosis in patients with bullous pemphigoid (BP) can be challenging. Treatment options pose unique risks in these patients as surgical wounds can have delayed wound healing and photodynamic therapy (PDT) may exacerbate their blistering disease. We report the successful use of PDT to treat actinic keratosis and skin cancers in two patients with BP, both of whom had excellent response to PDT and tolerated treatment without any bullous disease flares. Carefully selected patients with skin cancers and stable, well controlled BP can be safely considered for treatment using PDT...
March 31, 2017: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/28370377/analysis-of-apoptosis-associated-molecules-erythroid-differentiation-regulator-1-bcl-2-and-p53-in-actinic-keratosis-after-treatment-with-ingenol-mebutate
#11
Yu Ri Woo, Ji Hong Lim, Seo-Won Jeong, Dae Ho Cho, Hyun Jeong Park
AK is the most common cutaneous premalignant neoplasm precursor of malignant skin tumors. The aberrant apoptotic pathway is thought to be associated with pathogenesis of AK. Ingenol mebutate has been shown to be effective and safe for treatment of AK. However, the effect of ingenol mebutate on apoptosis-related molecules using human skin samples has not been studied well. Erythroid differentiation regulator 1 (Erdr1) was recently reported to play a crucial role in malignant skin cancers like malignant melanoma...
March 31, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28370134/red-light-photodynamic-therapy-for-actinic-keratosis-using-37%C3%A2-j-cm-2-fractionated-irradiation-with-12-3%C3%A2-mw-cm-2-after-30-minutes-incubation-time-compared-to-standard-continuous-irradiation-with-75%C3%A2-mw-cm-2-after-3-hours-incubation-time-using-a-mathematical
#12
Anne-Sophie Vignion-Dewalle, Gregory Baert, Laura Devos, Elise Thecua, Claire Vicentini, Laurent Mortier, Serge Mordon
OBJECTIVE AND STUDY DESIGN: Photodynamic therapy (PDT) is an emerging treatment modality for various diseases, especially for dermatological conditions. Although, the standard PDT protocol for the treatment of actinic keratoses in Europe has shown to be effective, treatment-associated pain is often observed in patients. Different modifications to this protocol attempted to decrease pain have been investigated. The decrease in fluence rate seems to be a promising solution. Moreover, it has been suggested that light fractionation significantly increases the efficacy of PDT...
April 2, 2017: Lasers in Surgery and Medicine
https://www.readbyqxmd.com/read/28367259/united-states-food-and-drug-administration-product-label-changes
#13
Leon Kircik, Julie C Sung, Linda Stein-Gold, Gary Goldenberg
Once a drug has been approved by the United States Food and Drug Administration and is on the market, the Food and Drug Administration communicates new safety information through product label changes. Most of these label changes occur after a spontaneous report to either the drug manufacturing companies or the Food and Drug Administration MedWatch program. As a result, 400 to 500 label changes occur every year. Actinic keratosis treatments exemplify the commonality of label changes throughout the postmarket course of a drug...
February 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/28358590/cellulitis-secondary-to-liquid-nitrogen-cryotherapy-case-report-and-literature-review
#14
Christina M Huang, Emily Y Lu, Mark G Kirchhof
BACKGROUND: Liquid nitrogen cryotherapy is a commonly used technique to treat a wide variety of dermatologic conditions including actinic keratoses, non-melanoma skin cancers, verrucae, and seborrheic keratoses. The risks associated with liquid nitrogen cryotherapy are important to know and discuss with patients prior to treatment. OBJECTIVE: We report a case of cellulitis secondary to liquid nitrogen cryotherapy for actinic keratosis. We sought to review the literature for an estimate of secondary infection rates following cryotherapy treatment...
March 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28358282/efficacy-of-a-film-forming-medical-device-containing-sunscreen-50-and-piroxicam-0-8-in-actinic-keratosis-and-field-cancerization-a-multicenter-assessor-blinded-3-month-trial
#15
Mario Puviani, Chiara Galloni, Silvia Marchetti, Paolo Sergio Pavone, Silvia Lovati, Giuseppe Pistone, Valentina Caputo, Giovanna Tilotta, Giuseppe Scarcella, Elena Campione, Laura Diluvio, Virginia Garofalo, Luca Bianchi, Massimo Milani
INTRODUCTION: Sunscreen protection in subjects with actinic keratosis (AK) is highly recommended to prevent clinical evolution of this in situ skin cancer condition. Use of topical anti-cyclooxygenase drugs such as diclofenac and piroxicam reduces the number of lesions and improves the cancerization field. A film-forming medical device in a cream formulation containing organic and inorganic sun-filters (50+ SPF) and piroxicam 0.8% (ACTX) has shown in a pilot, single-center, open trial to reduce AK lesions improving the cancerization field...
April 20, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28342266/increased-number-of-mast-cells-in-the-dermis-in-actinic-keratosis-lesions-effectively-treated-with-imiquimod
#16
Satomi Oyama, Yoko Funasaka, Shin-Ichi Tsuchiya, Seiji Kawana, Hidehisa Saeki
Actinic keratosis (AK) is a cutaneous cancer in situ which develops as a result of excessive exposure to ultraviolet (UV). Toll-like receptor (TLR)7 agonist imiquimod is a topical immune response modifier and is effective for the treatment of non-melanoma skin cancers. Recently, the diagnostic role of the dermatoscope has been reported in the course of treatment of AK. In addition, mast cells are now considered to contribute to both the innate and adaptive immune systems in topical imiquimod therapy. We assessed the effect of imiquimod treatment by dermatoscopic and immunohistochemical findings in 14 patients with a total of 21 AK lesions...
March 24, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28329662/the-preneoplastic-genome-transcriptomic-drivers-of-squamous-cell-carcinoma-development
#17
Kenneth Y Tsai
Cutaneous squamous cell carcinoma (cuSCC) comprises 15-20% of all skin cancers, accounting for over 700,000 cases in the U.S. annually. Most cuSCC arise in association with a distinct precancerous lesion, the actinic keratosis (AK). In order to identify potential targets for molecularly targeted chemoprevention, we performed integrated cross-species genomic analysis of cuSCC development through the preneoplastic AK stage using matched human samples and a solar UV- driven Hairless mouse model. We performed RNA-seq and microRNA-seq on samples from both patients undergoing Mohs surgery and the mouse model...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329661/predictors-of-actinic-keratosis-count-in-those-with-multiple-keratinocyte-carcinomas
#18
Julia A Siegel, Adam J Luber, Martin A Weinstock
Actinic keratoses (AKs) are frequently treated in the U.S., impacting an estimated 40 million people in 2004 and costing over $1 billion annually. AKs are a major public health concern because of their high prevalence, substantial cost, and potential for malignant transformation to keratinocyte carcinoma (KC). In this analysis, predictors of AK count were explored using pre-randomization baseline data from two large randomized trials of veterans with multiple prior KCs (n=932 and n=1131). Multivariate analyses were conducted to elucidate associations between AK count and several demographic and health related factors...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329637/dermatological-screening-of-an-elderly-population-the-rotterdam-study
#19
Martijn G H Sanders, Joris A C Verkouteren, Luba M Pardo
BackgroundThe recent WHO burden of disease project showed that the non-fatal skin disease related burden is high, but also that prevalence rates of many common skin diseases are not well documented. The aim of this study is to give an overview of (untreated) skin diseases in a population based sample of elderly.MethodsIn 2010, a full body skin examination (FBSE) was embedded in the Rotterdam Study, a prospective population based cohort study of an elderly white-skinned population in the Netherlands. The examination was conducted by a dermatology-trained physician and focused on most common skin diseases (e...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329611/terap%C3%A3%C2%AAutica-fotodin%C3%A3-mica-com-metil-aminolevulinato-no-tratamento-de-les%C3%A3%C2%B5es-refract%C3%A3-rias-de-micose-fung%C3%A3-ide-resposta-cl%C3%A3-nica-e-histol%C3%A3-gica-mantida-em-dois-doentes
#20
Ana Isabel Teixeira, João Maia E Silva
According to the guidelines proposed by the National Comprehensive Cancer Network, early-stage Mycosis Fungoides (MF) should be treated with skin-directed therapies such as topical steroids or retinoids, topical chemotherapy (carmustin and nitrogen mustard), photochemotherapy, and superficial radiotherapy. Patients with refractory lesions to these therapeutic options are particularly challenging. Photodynamic Therapy (PDT) has been approved to treat cutaneous neoplastic and pre-neoplastic lesions such as superficial basal cell carcinoma, Bowen disease and actinic keratosis...
September 15, 2016: Dermatology Online Journal
keyword
keyword
3039
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"